COX2 antibody (AA 442-572)

Catalog No. ABIN7875030

The Mouse Monoclonal anti-COX2 antibody is suitable to detect COX2 in samples from Human. It has been validated for IHC (p).

Quick Overview for COX2 antibody (AA 442-572) (ABIN7875030)

Target: COX2 (Cytochrome C Oxidase Subunit II (COX2))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This COX2 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: COX2-2377

Product Details anti-COX2 Antibody

Binding Specificity: AA 442-572

Purpose: COX2 Antibody / PTGS2 (azide and preservative free)

Purification: Protein A/G affinity

Immunogen: A portion of amino acids 442-572 was used as the immunogen for the COX2 antibody.

Isotype: IgG2a, kappa

Application Details

Application Notes: Optimal dilution of the COX2 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: -20 °C

Storage Comment: Aliquot the COX2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for COX2

Target: COX2 (Cytochrome C Oxidase Subunit II (COX2))

Alternative Name: COX2

Background: Prostaglandins are a diverse group of autocrine and paracrine hormones that mediate many cellular and physiologic processes. Prostaglandin H2 (PGH2) is an intermediate molecule in formation of the prostaglandins. Cyclooxygenase-1 (Cox-1) and cyclooxygenase-2 (COX2) are prostaglandin synthases that catalyze the formation of PGH2 from arachidonic acid (AA). Cox-1 and COX2 are isozymes of prostaglandin-endoperoxidase synthase (PTGS). Cox-1 is constitutively expressed in most tissues and is thought to serve in general housekeeping functions. COX2 is efficiently induced in migratory cells responding to pro-inflammatory stimuli and is considered to be an important mediator of inflammation. Both enzymes are targets for the nonsteroidal therapeutic anti-inflammatory drugs, NSAIDs. COX2 expression is significantly increased in 85-90 % of human colorectal adenocarcinomas whereas levels of COX-1 are not changed.

UniProt: P35354

Pathways: Brown Fat Cell Differentiation, Positive Regulation of fat Cell Differentiation